Lirilumab

Names

[ Name ]:
Lirilumab

Biological Activity

[Description]:

Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research[1][2].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> Others >> Others

[In Vivo]

Lirilumab (intravenous injection; 15 mg/kg; once) treatment enhances survival rate of mice injected with tumor[2]. Animal Model: Rag1KO-Tg KIR mice injected with tumor cells[2] Dosage: 15 mg/kg Administration: intravenous injection; 15 mg/kg; once Result: Showed 6 of 7 mice survival over a 100-day period, whereas untreated or IC-treated mice all died.

[References]

[1]. Hanna GJ, et al. Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 Feb 1;28(3):468-478.

[2]. Kohrt HE, et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood. 2014 Jan 30;123(5):678-86.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.